Letter to the Editor
Leukemia advance online publication 22 October 2009; doi: 10.1038/leu.2009.214
Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin
P Chevallier1,2, T Prebet3, A Pigneux4, M Hunault5, J Delaunay1,2, F Perry4, L Lode1,2, S Richebourg1,2, O Blanchet5, N Vey3, N Ifrah5, N Milpied4, D Blaise3, J-L Harousseau1,2 and M Mohty1,2
- 1Service d'Hématologie Clinique, CHU, Nantes, France
- 2Université de Nantes, INSERM U892, Nantes, France
- 3Département d'Hématologie, Institut Paoli-Calmettes, Marseille, France
- 4Service d'Hématologie Clinique, CHU de Bordeaux, France
- 5Service d'Hématologie Clinique, CHU d'Angers, France
Correspondence: P Chevallier, E-mail: patrice.chevallier@chu-nantes.fr
